GlassScriptPhysician profile
Beth R Braver
NPI 1225032105
$18,749.16
in general payments reported to CMS, 2019-2025
76 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,140 · 2020: $2,928 · 2021: $3,230 · 2022: $2,693 · 2023: $2,661 · 2024: $2,161 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,758.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,873.48 | 2019-2025 | Airsupra, Farxiga, Tezspire |
| Novo Nordisk INC | $1,819.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,412.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,257.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,181.38 | 2019-2025 | |
| Amgen INC. | $1,094.07 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $856.44 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.47 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Abbvie INC. | $575.21 | 2020-2024 | Qulipta, Ubrelvy, Vraylar |
| Janssen Pharmaceuticals, INC | $490.47 | 2019-2025 | Xarelto, Spravato |
| Amarin Pharma, INC. | $425.80 | 2019-2023 | |
| Astellas Pharma US INC | $418.87 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.01 | 2019-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $369.14 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $363.30 | 2021-2024 |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Braver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.